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METHODS: We examined the concentration of the pharmaceutical market by using 
the Herﬁndahl-Hirschmann Index. We calculated the index for 12 different medicine 
groups in 2002–2008. Ten of these groups were prescription medicines and two were     
self-care medicines. The index is calculated by summing up the squares of the market 
shares for all the ﬁrms operating in the medicine group. It is important that all medi-
cines in each group can be substituted to each other. The index value varies between 
1/n  1, n  ﬁrms. Greater value of the HHI indicates greater concentration. If HHI 
is below 0.18 there is no concentration at all. RESULTS: In 2002 the total HHI 
average for the 12 groups was 0.30 as in 2008 it was 0.22. In anti-dementia drugs    
the index dropped from 0.48 to 0.23. In triptans the index dropped from 0.40 to 0.17. 
The smallest index was seen in antiallergics. In 2002 the index in this group was 0.14 
and in 2008 it was 0.12. In 2008 the most concentrated group according to the index 
was the protone pump inhibitors. The index in this group was 0.38. CONCLUSIONS: 
From 2002 to 2008 the concentration in medicine groups has clearly diminished. The 
difference between these groups is partly due to patents. The two self-care medicine   
groups used in the study are clearly less concentrated than the prescription medicine 
groups. However, the average for all 12 groups is 0.22 and exceeds the index point 
of 0.18. This indicates that among the medicine groups used in calculations the market 
is still concentrated.
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OBJECTIVES: To examine if the introduction of a lump sum reimbursement system 
for pharmaceuticals in Belgian hospitals for hospitalized patients resulted in shifts 
in Health Insurance expenses (third party payer) for pharmaceuticals from an in-
patient setting (hospitalized patients) to an out-patient setting (day clinic, public 
pharmacies, . . .), based on an analysis of ﬁnancial data of NIHDI. METHODS: In july 
2006, a partial (approximately 75% of the expenses) lump sum reimbursement 
system was introduced for standard medication (excluding new expensive drugs, 
oncolytics, orphan drugs, . . .) ﬁxing budgets per hospital, per hospitalization, based 
on patient proﬁles (APRDRG, All patients Reﬁned Diagnosis Related Groups) and 
ﬁnancial data. Using registered ﬁnancial data from NIHDI the evolution of the Health 
Insurance expenses for pharmaceuticals in hospitals was examined. RESULTS: 
The yearly expenses for pharmaceuticals for hospitalized patients grew with 8.0%, 
0.2%, 2.0%, 0.1% and 1.6% in the period 2003–2008. For patients in day 
clinic the growth was respectively 23.7%, 11.7%, 5.8%, 19.3% and 17,9%. 
For patients in public pharmacies these ﬁgures were 8.2%, 1.2%, 2.3%, 6.2% 
and 12.2%. CONCLUSIONS: Evaluation of the data shows no changes in the trend 
in evolution of the expenses for any type of patients other than leveling of the growth 
in the period 2005–2006—similar to the evolution of expenses for pharmaceuticals 
in the other OECD countries—and a additional growth in expenses in public pharmacies 
(6,2%) due to the inclusion of self-employed persons in the general system for com-
pulsory health insurance in 2008. Analysis shows no shifts in expenses from one 
setting to another.
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OBJECTIVES: In view of the 6-fold increase in drug expenditure over the past decade 
in Ireland, we set out to identify primary areas of utilisation and expenditure under 
the Community Drugs Schemes and explore strategies for cost containment. 
METHODS: We examined the Statistical Analysis of Claims and Payments for 
2007/2008 from the Primary Care Reimbursement Service (PCRS). This is a deﬁnitive 
measure of general practitioner prescribing rates and enabled us to determine utiliza-
tion and expenditure. We applied the autoregressive integrated moving average 
(ARIMA) model to the national prescribing database to predict future expenditure on 
medicines. RESULTS: In 2008 expenditure under the Community Drugs Schemes was 
a2.289 billion with over 60.5 million prescription items. The ARIMA model predicts 
that expenditure will continue to rise reaching a2.3–a3 billion by 2012. The 60.5 
million prescription items are distributed as follows: General Medical Services Scheme 
(GMS) 73%, Long Term Illnesses Scheme 4% (both free to patients), Drug Payments 
Scheme 22%, High Technology Drugs and others account for the remaining 1%. The 
major therapeutic classiﬁcations by cost under the GMS are Cardiovascular System 
23.9%, Nervous System 20.5%, Alimentary Tract and Metabolism 15.4%. Cost 
containment measures could include: increasing generic drug utilisation rates from 
18.3% (2.4% unbranded, 15.9% branded; EU average ^50%); decreasing wholesale 
margin from 15%; changing current drug schemes by introducing disinvestment 
measures and patient co-payments; reducing the pharmacy 50% mark-up and intro-
ducing reference pricing whilst continuing to reward innovation. CONCLUSIONS: 
It is clear that the current trend of increasing drug expenditure will continue and 
the measures we have suggested above would be efﬁcient strategies for cost 
containment.
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OBJECTIVES: Global pharmaceutical companies often conduct coordinated, multi-
country studies to elicit information from payers and those who inﬂuence their deci-
sions. Such studies can inﬂuence global product value strategy and increase the 
likelihood of positive pricing and reimbursement (P&R) decisions. Differences in P&R 
systems across markets must be considered. The aim of this study was to compare 
payer roles in three pharmaceutical markets (UK, Spain, Canada), and to evaluate 
the usefulness of various qualitative research methods in eliciting information to 
inform a global product value strategy. METHODS: We conducted a review of pub-
licly available guidance and qualitative payer research to develop a framework for 
comparing optimal approaches to qualitative payer research. We compared the 
levels at which pricing, reimbursement, and market access decisions are made (e.g., 
national, regional, local, hospital), bodies inﬂuencing payer decisions (e.g., health 
technology assessment agencies), and the processes of engagement among physicians, 
patients, and payers. Implications of various qualitative and quantitative research 
techniques on a pharmaceutical company’s ability to devise an effective global strategy 
are discussed. RESULTS: Treatment location (outpatient drug, hospital only) and type 
of prescriber must be considered when determining the research strategy in Spain. 
In Canada, provincial drug plans make reimbursement decisions for outpatient 
drugs considering Common Drug Review recommendations. Hospital formulary com-
mittees assess drugs for hospital use. NICE, the Scottish Medicines Consortium and 
the All Wales Medicines Strategy Groups make decisions at the national level in the 
UK while Primary Care Trusts make funding decisions in the absence of NICE 
appraisal in England. CONCLUSIONS: For multi-country payer research to be useful 
for devising a global value strategy it is important to understand the pricing and 
reimbursement systems in different countries and to identify properly the key 
stakeholders.
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OBJECTIVES: Assessment of health technology (HTA), including pharmaceuticals, 
devices, procedures and organizational systems plays an increasingly important 
role in health care systems by providing structured, evidence-based input to policy-
making. HTA is ﬁrmly established in Europe, North America and Australasia, and is 
growing rapidly in Asia and Latin America. We investigated the organisation and 
inﬂuence of HTA in middle-income countries on real decision-making over pharam-
ceutical budgets. METHODS: We selected middle-income countries where HTA 
activities are establihsed to some extent: Argentina, Brazil, China, Colombia, Israel, 
Mexico, Philippines, Korea, Taiwan, Thailand, and Turkey. We collected and reviewed 
relevant information to describe the health care and reimbursement systems and how 
HTA relates to coverage decision making of pharmaceuticals using a common tem-
plate. The country proﬁles were supplemented by information from a structured 
web-survey among professionals working in public and private health insurance, 
industry, regulatory authorities, ministries of health, academic units or HTA agencies. 
RESULTS: The use and implementation of HTA recommendations in reimbursement 
decision-making is still in its early stages. We found that in South Korea, Taiwan, 
Brasil and Mexico HTA was more developed, with guidelines for manufacturers 
submissions, a link to the pricing of new treatments and some requirement for data 
to be adapted for local costs epidemiology. CONCLUSIONS: The study provides 
evidence of the development of HTA in coverage decision making in middle-income 
countries. Increased health care spending and the resulting access to modern technol-
ogy give a strong impetus to HTA. The assessment and regulation of pharmaceuticals 
are advanced in relation to other technologies. HTA is developing with uneven speed 
in middle-income countries; many countries are building on the organisational and 
methodological experience from established HTA agencies in Europe, Australia and 
Canada.
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OBJECTIVES: Elicit the individual willingness to pay (WTP) for a QALY. METHODS: 
Web-based contingent analysis included 1091 respondents, representative of the Dutch 
population. Individuals solved 5 scenarios with two health states each. They initially 
valued health states on VAS scale, then indicated which health state was worse and 
ﬁnally expressed their WTP for avoiding a given decline in health. WTP was elicited 
in an open-ended format and from a payment scale. Respondents had to indicate the 
degree of certainty in the answers provided. WTP/QALY was calculated one for every 
utility elicitation technique, WTP elicitation technique (payment scale and open-ended 
questions) and each scenario. The heterogeneity in WTP/QALY ratios was examined 
from the perspective of 1) household income, and 2) the level of certainty in WTP 
